TransCode Therapeutics Appoints Life Sciences Veteran Jack E. Stover to Board of Directors

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the appointment of Jack E. Stover to its Board of Directors. Mr. Stover will serve on the Audit Committee and the Nominating Committee, with Dr. Magda Marquet stepping down from the Audit Committee. This board-level change comes as TransCode, a clinical-stage oncology company, continues to advance its pipeline focused on treating metastatic disease.

Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies. His extensive background spans drug development, diagnostics, specialty pharmaceuticals, and capital formation. The company expects him to contribute significant operational, financial, and strategic expertise as it progresses its RNA and immuno-oncology pipeline designed for the treatment of high-risk and advanced cancers.

TransCode is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. This focus on a specific biomarker represents a targeted approach to a major challenge in oncology. In addition to TTX-MC138, TransCode maintains a portfolio of other first-in-class RNA therapeutic candidates. These candidates are designed to overcome the historical challenges of RNA delivery, potentially unlocking therapeutic access to a variety of novel genetic targets relevant to treating multiple cancers.

The appointment of a seasoned executive like Mr. Stover signals a strategic strengthening of governance as the company moves its clinical programs forward. For investors and the oncology community, board appointments with deep industry experience often correlate with enhanced strategic oversight during critical development phases. The latest news and updates relating to the company are available in its newsroom at https://ibn.fm/RNAZ.

The press release was distributed via InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire focuses on wire-grade press release syndication and provides services including article syndication to over 5,000 outlets, enhanced press release features, and social media distribution. For more information on the distribution service, please visit https://www.InvestorWire.com. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.

For TransCode, navigating the complexities of clinical development for metastatic cancers requires not only scientific innovation but also robust financial and operational strategy. The addition of Mr. Stover's expertise to the board could provide valuable guidance in these areas, potentially impacting the company's ability to advance its TTX platform and bring new treatment options to patients facing advanced-stage disease. The broader implication lies in the continued validation of RNA-based approaches in oncology, where successful delivery remains a significant hurdle. TransCode's progress, supported by experienced leadership, contributes to the evolving landscape of targeted cancer therapies.